Australian startup Ferronova has raised a further

澳大利亚初创公司Ferronova又筹集了

$6 million

600万美元

to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence following surgery.

推进一种新型纳米粒子影像引导手术解决方案的商业化，该方案旨在改善癌细胞的识别，并降低术后未检测到复发的风险。

Ferronova's super-paramagnetic iron oxide nanoparticles bind to cells found in lymph nodes which aim to enable identification of tissue that could contain cancerous cells. The technology aims to support more informed surgical decision-making and address the problem that cancer cells are often not identified by current imaging and rogue cells may remain undetected in surgery..

Ferronova的超顺磁性氧化铁纳米颗粒会与淋巴结中的细胞结合，旨在识别可能含有癌细胞的组织。该技术旨在支持更明智的手术决策，并解决当前成像技术通常无法识别癌细胞以及手术中可能遗留未被发现的游离癌细胞的问题。

Ferronova's latest

费雷诺瓦的最新成果

$6 million

600万美元

round was led by existing investors Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners and Renew Pharmaceuticals (a subsidiary of

本轮由现有投资者Uniseed/UniSuper、南澳大利亚风险资本基金、Artesian Venture Partners和Renew Pharmaceuticals（一家子公司）领投。

Singapore

新加坡

-based Ultragreen.ai). The latest capital raising brings the total generated in Series A rounds to

基于Ultragreen.ai）。最新的融资使A轮融资总额达到

$17.5 million

1750万美元

.

。

The startup is currently undertaking a 60 patient, two-year trial of the technology in stomach and oesophageal cancers – with 54 patients enrolled to date and completion expected in early 2026. The trial involves leading national research centres including the Olivia Newton John Cancer Centre, Peter MacCallum Cancer Centre, Royal Adelaide Hospital and Flinders Medical Centre.

这家初创公司目前正在开展一项涉及胃癌和食道癌的60名患者、为期两年的技术试验——迄今为止已有54名患者注册，预计将在2026年初完成。该试验涉及多家领先的国家级研究中心，包括奥利维亚·牛顿-约翰癌症中心、彼得·麦卡勒姆癌症中心、皇家阿德莱德医院和弗林德斯医疗中心。

Plans are underway to continue research in the US over the next two years..

计划在未来两年内继续在美国进行研究。

Ferronova CEO

费罗诺瓦首席执行官

Stewart Bartlett

斯图尔特·巴特利特

said that while surgery remains the only curative treatment for most patients, surgical research only attracts 0.1% of global cancer research funding.

表示虽然手术仍然是大多数患者的唯一治愈性治疗方法，但外科研究仅吸引了全球癌症研究资金的0.1%。